Entera Bio (NASDAQ:ENTX) Stock Price Down 3% – Here’s What Happened

Entera Bio Ltd. (NASDAQ:ENTX) fell 3% during mid-day trading on Wednesday . The stock traded as low as $1.24 and last traded at $1.30. 285,757 shares were traded during mid-day trading, an increase of 69% from the average session volume of 169,135 shares. The stock had previously closed at $1.34.

Wall Street Analyst Weigh In

ENTX has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Entera Bio in a research note on Monday, February 9th. Wall Street Zen raised shares of Entera Bio to a “sell” rating in a research report on Saturday, December 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Entera Bio currently has an average rating of “Hold” and a consensus price target of $10.00.

Entera Bio Stock Performance

The firm has a market capitalization of $59.62 million, a P/E ratio of -5.20 and a beta of 1.83. The firm has a 50 day moving average price of $1.53 and a two-hundred day moving average price of $1.98.

Hedge Funds Weigh In On Entera Bio

Hedge funds have recently added to or reduced their stakes in the company. Bessemer Group Inc. bought a new stake in Entera Bio during the second quarter worth approximately $268,000. Seven Fleet Capital Management LP bought a new position in shares of Entera Bio in the fourth quarter valued at approximately $263,000. Jane Street Group LLC boosted its holdings in shares of Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after buying an additional 43,536 shares during the period. Schonfeld Strategic Advisors LLC boosted its holdings in shares of Entera Bio by 5.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after buying an additional 29,629 shares during the period. Finally, Citadel Advisors LLC grew its stake in Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares during the last quarter. Institutional investors and hedge funds own 14.11% of the company’s stock.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.